Artboard 1@2x.png

Prior to the launch of our product, there were 26 FDA-approved sexual dysfunction drugs for men and none for women. Now women have a treatment option.

Artboard 2@2x.png

In 2015, Sprout was acquired by Valeant for $1B, but our mission never left us. Two years later, Sprout was reestablished with our CEO Cindy Eckert back at the helm. We will get this right for women.

Artboard 3@2x.png

There are millions of women who continue to look for answers about Hypoactive (low) Sexual Desire Disorder (HSDD) and frustrating low libido. With our boxing gloves back on, we are making our product affordable and accessible.

News & Press

Sept 11, 2019, 08:30 ET

Summary of Recent Regulatory Guidance for Addyi®, the First and Only Pill for Hypoactive Sexual Desire Disorder

Apr 12, 2019, 11:55 ET

The Food and Drug Administration (FDA) Determines that Women Taking Addyi May Safely Consume Alcohol